Ziagen Interactions
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or
zidovudine or the combination of lamivudine and zidovudine. No clinically significant changes to lamivudine or
zidovudine pharmacokinetics were observed following concomitant administration of abacavir.
Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of abacavir
causing an increase in overall exposure .
The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. In a
study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of
ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
This alteration will not result in a methadone dose modification in the majority of patients; however, an increased
methadone dose may be required in a small number of patients.
Ziagen Contraindications
Abacavir tablets and oral solution are contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products. Following a hypersensitivity reaction to abacavir, NEVER restart Abacavir or any other abacavir-containing product. Fatal rechallenge reactions have been associated with readministration of abacavir to patients with a prior history of a hypersensitivity reaction to abacavir. Abacavir tablets and oral solution are contraindicated in patients with moderate or severe hepatic impairment.
Additional information about Ziagen
Ziagen Indication: For the treatment of HIV-1 infection, in combination with other antiretroviral agents.
Mechanism Of Action: Ziagen is a carbocyclic synthetic nucleoside analogue. Intracellularly, abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.
Drug Interactions: Ethanol Partly metabolized through the alcohol dehydrogenase enzyme system. Alcohol increases the area under the curve ( about 41% ) of Ziagen.
Food Interactions: Take without regard to meals.
Avoid alcohol.
Ziagen is partly metabolised through the alcohol-dehydrogenase enzyme system.
Alcohol significantly increases abacavir's area under the curve (about 41%).
Generic Name: Abacavir
Synonyms: ABC
Drug Category: Anti-HIV Agents; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Drug Type: Small Molecule; Approved
Other Brand Names containing Abacavir: Ziagen;
Absorption: Rapid and extensive after oral administration (83% bioavailability)
Toxicity (Overdose): Some myocardial degeneration has been noticed in rats and mice
Protein Binding: Moderate (approximately 50%)
Biotransformation: Hepatic, by alcohol dehydrogenase and glucuronosyltransferase to a 5′-carboxylic acid metabolite and 5′-glucuronide metabolite, respectively. These metabolites have no antiviral activity. Abacavir is not significantly metabolized by cytochrome P450 enzymes.
Half Life: 1.54 ± 0.63 hours
Dosage Forms of Ziagen: Tablet Oral
Solution Oral
Chemical IUPAC Name: [(1R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1-cyclopent-2-enyl]methanol
Chemical Formula: C14H18N6O
Abacavir on Wikipedia: http://en.wikipedia.org/wiki/Abacavir
Organisms Affected: Human Immunodeficiency Virus